Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of IVL3004 and IVL4002 in Healthy Subjects
NCT05620940Phase 1Recruiting
- Sponsor
- Inventage Lab
- Start
- Sep 2024
- Primary completion
- Dec 2025
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of IVL3004 and IVL4002 in opioid use disorder (OUD), alcohol dependence and multiple sclerosis (MS) (4 arms), sponsored by Inventage Lab. Primary endpoints: Area Under the Concentration-Time Curve from time 0 to 240 hours, Maximum Plasma Concentration and 3 more. Started Sep 2024; status: recruiting.
02
Drugs
IVL3004IVL4002
03
Conditions
opioid use disorder (OUD)alcohol dependencemultiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05620940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620940.